A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model

Highlights • Radiotherapy leads to side effects because it affects normal tissues near the target. • Thoracic radiotherapy can cause radiation pneumonitis and pulmonary fibrosis. • Rosiglitazone has anti-inflammatory, antifibrotic and antineoplastic properties. • Rosiglitazone reduced signs of radia...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-12, Vol.90 (3), p.405-409
Main Authors: Mangoni, Monica, Sottili, Mariangela, Gerini, Chiara, Bonomo, Pierluigi, Bottoncetti, Anna, Castiglione, Francesca, Franzese, Ciro, Cassani, Sara, Greto, Daniela, Masoni, Tatiana, Meattini, Icro, Pallotta, Stefania, Passeri, Alessandro, Pupi, Alberto, Vanzi, Eleonora, Biti, Giampaolo, Livi, Lorenzo
Format: Article
Language:English
Subjects:
Animals
Cell Line, Tumor
Cell Survival - radiation effects
Disease Models, Animal
Hematology, Oncology and Palliative Medicine
Humans
Lung Injury - diagnostic imaging
Lung Injury - drug therapy
Lung Injury - metabolism
Lung Injury - pathology
Mice
PPAR gamma - agonists
PPARgamma agonists
Pulmonary/Respiratory
Radiation Injuries, Experimental
Radiation, Ionizing
Radiation-induced lung toxicity
Radiation-Protective Agents - pharmacology
Radioprotection
Radiotherapy
Radiotherapy - adverse effects
Thiazolidinediones - pharmacology
Tomography, X-Ray Computed
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Radiotherapy leads to side effects because it affects normal tissues near the target. • Thoracic radiotherapy can cause radiation pneumonitis and pulmonary fibrosis. • Rosiglitazone has anti-inflammatory, antifibrotic and antineoplastic properties. • Rosiglitazone reduced signs of radiation-induced lung toxicity in a mouse model. • Rosiglitazone could be proposed as a radioprotective agent in thorax irradiation.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.11.005